Cart
sales@molnova.com
Isbogrel
CAS No. 89667-40-3
Isbogrel( —— )
Catalog No. M34289 CAS No. 89667-40-3
Isbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 532 | Get Quote |
|
| 5MG | 787 | Get Quote |
|
| 10MG | 1074 | Get Quote |
|
| 25MG | 1463 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIsbogrel
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis.
-
DescriptionIsbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorProstaglandin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number89667-40-3
-
Formula Weight281.35
-
Molecular FormulaC18H19NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=C\CCCCC(O)=O)(\C1=CC=CC=C1)/C=2C=CC=NC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Imidapril HCl
Imidapril HCl is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 2.6 nM, used for the treatment of hypertension.
-
L-798106
L-798106 (CM9) is a selective and potent prostaglandin-like EP3 receptor antagonist that inhibits EP4, EP1, and EP2 receptors, suppresses levels of pro-inflammatory cytokines in atherosclerosis, and attenuates PGE2-induced cough.
-
Tafluprost
Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.
